NeuroSense Therapeutics (NRSN) Stock Price, News, Quotes-Moomoo

$NeuroSense Therapeutics (NRSN.US)$
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
NeuroSense Therapeutics (NASDAQ: NRSN) has secured a Type C meeting with the FDA on November 6, 2024, to discuss the design of its Phase 3 clinical trial for PrimeC, a potential ALS treatment. The meeting will focus on finalizing trial design and reviewing NDA submission readiness.
PrimeC has demonstrated significant results in reducing disease progression markers. The co...

Jaguar8

Oct 15 08:16

NEWS

$NeuroSense Therapeutics (NRSN.US)$
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
NeuroSense Therapeutics (Nasdaq: NRSN) has provided an update on its plans to file for early commercialization approval for PrimeC, its ALS treatment, under Health Canada's Notice of Compliance with Conditions (NOC/c) policy. The company plans to submit its dossier in Q2 2025, with an expected regulatory decision by Q1 2026.
The submissi...

Jaguar8

Oct 9 08:01

NEWS

$NeuroSense Therapeutics (NRSN.US)$
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
NeuroSense Therapeutics (NASDAQ: NRSN) has initiated the regulatory process for early commercialization approval of PrimeC, its ALS treatment, under Health Canada's Notice of Compliance with Conditions (NOC/c) policy. This decision follows positive Phase 2b trial results showing PrimeC reduces ALS disease progression by 36% (p=0.009) and improves survival rates by 4...